Glenmark and Pfizer Partner To Unveil Abrocitinib in India

Glenmark said it has collaborated with Pfizer to send off abrocitinib in India utilized for treatment of moderate-to-extreme atopic dermatitis (Promotion). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO.

Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies, as per economic times.

The first oral therapy for adults with moderate-to-severe AD, a chronic skin disease that results in skin barrier defects and inflammation, is abrocitinib. Abrocitinib, a drug that blocks Janus kinase 1 (JAK1), reduces itching quickly, maintains disease control, and enhances quality of life.

Abrocitinib is available under the brand name CIBINQO in more than 35 countries around the world, including the United States, Japan, and China.

"Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organizations to make this breakthrough therapy available to patients and physicians across our country,” said Meenakshi Nevatia, country president and managing director of Pfizer India.

“The prevalence of atopic dermatitis in India has been reported to be increasing owing to changes in environmental factors with symptoms appearing during the initial years of life in around 80% of patients," said Alok Malik, president and business head, India Formulations, Glenmark.

"Being a leader in dermatology therapy in India, this partnership will help us ensure availability of this effective treatment for the Indian patients suffering from moderate-to-severe AD; and further strengthen our position in the dermatology therapy space,” Malik added.